Literature DB >> 28863328

Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.

Björn W Karlson1, Michael K Palmer2, Stephen J Nicholls3, Philip J Barter4, Pia Lundman5.   

Abstract

BACKGROUND AND AIMS: The effectiveness of statins in the treatment of dyslipidaemia and reduction of cardiovascular risk is well established. However, the association of statin-mediated lipid effects with age and gender is unclear. This study aimed to determine whether age and gender are associated with statin-mediated changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and non-HDL-C.
METHODS: Individual patient data (n = 32,258) were obtained from VOYAGER. Least-squares mean percentage change from baseline in LDL-C, non-HDL-C and HDL-C with atorvastatin 10-80 mg, rosuvastatin 5-40 mg or simvastatin 10-80 mg was estimated in women aged <70 years, women aged ≥70 years, men aged <70 years and men aged ≥70 years.
RESULTS: All statins and doses gave significant dose-dependent reductions in LDL-C and non-HDL-C, and increases in HDL-C, in all four patient groups. A 2.1% greater reduction in LDL-C was observed in women, compared with men (p < 0.0001). Patients aged ≥70 years experienced a 2.7% greater reduction in LDL-C compared with younger patients (p < 0.0001). Similar results were also observed for statin-mediated changes in non-HDL-C. Men experienced a significantly greater increase in HDL-C than women, and patients aged ≥70 years achieved a significantly greater increase than younger patients (both p = 0.001).
CONCLUSIONS: While statins improve the lipid profile in all gender and age groups analysed, the improvements are greater in women than in men and in those aged ≥70 years compared with those aged <70 years.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Age; Dyslipidaemia; Elderly; Gender; Statins; Women

Mesh:

Substances:

Year:  2017        PMID: 28863328     DOI: 10.1016/j.atherosclerosis.2017.08.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Effects of Estradiol Dose and Serum Estradiol Levels on Metabolic Measures in Early and Late Postmenopausal Women in the REPLENISH Trial.

Authors:  Intira Sriprasert; Howard N Hodis; Brian Bernick; Sebastian Mirkin; Wendy J Mack
Journal:  J Womens Health (Larchmt)       Date:  2020-07-09       Impact factor: 2.681

Review 2.  Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.

Authors:  Carolina Dagli-Hernandez; Yitian Zhou; Volker Martin Lauschke; Fabiana Dalla Vecchia Genvigir; Thiago Dominguez Crespo Hirata; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-08-17       Impact factor: 3.024

3.  Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.

Authors:  Carolina Dagli-Hernandez; Jéssica Bassani Borges; Elisangela da Silva Rodrigues Marçal; Renata Caroline Costa de Freitas; Augusto Akira Mori; Rodrigo Marques Gonçalves; Andre Arpad Faludi; Victor Fernandes de Oliveira; Glaucio Monteiro Ferreira; Gisele Medeiros Bastos; Yitian Zhou; Volker M Lauschke; Alvaro Cerda; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmaceutics       Date:  2022-04-27       Impact factor: 6.525

Review 4.  Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.

Authors:  Timothy Mark Reynolds; Alison Pottle; Sadat H Quoraishi
Journal:  Vasc Health Risk Manag       Date:  2021-05-21

5.  Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.

Authors:  Andrew R English; Bodhayan Prasad; Declan H McGuigan; Geraldine Horigan; Maurice O'Kane; Anthony J Bjourson; Priyank Shukla; Catriona Kelly; Paula L McClean
Journal:  Endocrinol Diabetes Metab       Date:  2022-03-04

6.  Effects of statin therapy and treatment duration on cardiovascular disease risk in patients with nephrotic syndrome: A nested case-control study.

Authors:  Xinliang Zou; Li Nie; Yi Liao; Zhihui Liu; Wanxiang Zheng; Xiaolong Qu; Xiang Xu; Haoran Qin; Haidong Wang; Jianping Liu; Guoxiang He; Tao Jing
Journal:  Pharmacotherapy       Date:  2022-03-03       Impact factor: 6.251

Review 7.  Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.

Authors:  Diego Estrada-Luna; María Araceli Ortiz-Rodriguez; Lizett Medina-Briseño; Elizabeth Carreón-Torres; Jeannett Alejandra Izquierdo-Vega; Ashutosh Sharma; Juan Carlos Cancino-Díaz; Oscar Pérez-Méndez; Helen Belefant-Miller; Gabriel Betanzos-Cabrera
Journal:  Molecules       Date:  2018-10-23       Impact factor: 4.411

8.  Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.

Authors:  Xuan Jin; Moo Hyun Kim; Ki Hoon Han; Soon Jun Hong; Jeong-Cheon Ahn; Jung-Hoon Sung; Jin-Man Cho; Han Cheol Lee; So-Yeon Choi; Kyounghoon Lee; Woo-Shik Kim; Moo-Yong Rhee; Ju Han Kim; Seung Pyo Hong; Byung Su Yoo; Eun Joo Cho; Jae-Hwan Lee; Pum-Joon Kim; Chang-Gyu Park; Min Su Hyon; Jin Ho Shin; Sang Hyun Lee; Ki Chul Sung; Jinyong Hwang; Kihwan Kwon; In-Ho Chae; Jeong-Sook Seo; Hyungseop Kim; Hana Lee; Yoonhwa Cho; Hyo-Soo Kim
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.